Please login to the form below
DLBCL
This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.
Another R&D flop for Incyte, but Jakafi keeps delivering
Meanwhile, Incyte was quick to point out that the failure of PI3K delta inhibitor INCB50465 in a form of NHL called diffuse large B cell lymphoma (DLBCL) does not affect phase
Latest news
-
CAR-Ts Kymriah and Yescarta step closer to approval in Europe
b cell lymphoma (DLBCL), the latter being the key battleground between it and Yescarta.
-
New trial results suggest CAR-T effects are durable in lymphoma
Updated results from the JULIET trial of the therapy in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) – reported at the European Haematology Association (EHA) congress over the ... Updated results from the TRANSCEND study in
-
Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more
While Bluebird Bio impressed with further strong data on beta thalassemia and sickle cell disease on Friday, the following data saw Novartis and Celgene both unveil longer-term data in DLBCL –
-
Daily Brief: Tagrisso's first line approval, EULAR and EHA, and why Stephen Hawking was wrong on NHS
Some of the most eyecatching data includes updates from Novartis on its CAR-T therapy Kymriah in (DLBCL) and r/r B-cell acute lymphoblastic leukemia (B-ALL) and bluebird’s
-
NHS chief pledges CAR-T support, but asks for pricing restraint
Kite’s CAR-T Yescarta (axicabtagene ciloleucel) was the first to be submitted for approval in Europe and is being reviewed by the EMA for diffuse large B-cell lymphoma (DLBCL), ... Meanwhile, Novartis’ Kymriah (tisagenlecleucel) has been filed for
More from news
Approximately 5 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl
-
Pharma deals in April 2015
its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
-
Current development and marketing of biosimilar monoclonal antibodies in Latin America
Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Celgene boosts CAR-T stake again with Bluebird Bio deal
That deal gave it rights to Juno’s lead CAR-T candidate JCAR017 (lisocabtagene maraleucel), which is in testing for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), as
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- GDPR and events. What does the pharma industry need to know?
- Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
- ‘Common Rulebook’ Brexit plans include medicines – but face backlash
- MaxCyte gets green light for solid tumour cell therapy
- Novartis rejects claims it misled Senate over Cohen links
- May’s Brexit plan cautiously welcomed by biopharma sector
PMHub
Solaris Health
The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...
Latest intelligence
- GDPR and events. What does the pharma industry need to know?
- ...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
- The rise of vertical integration in the US payer landscape
- Is it a solution to addressing the challenges of the value-based marketplace?...
Quick links
Infographics
